Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials (Q24599547)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633053%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

0 references

Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633053%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

prostate cancer

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633053%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633053%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

M M Regan

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633053%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

E K O'Donnell

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633053%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

W K Kelly

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633053%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

W Berry

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633053%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

S Urakami

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633053%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

N Kikuno

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633053%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

language of work or name

0 references

publication date

24 July 2009

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633053%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633053%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

21

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633053%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633053%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

312-318

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633053%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2852201

7 April 2017

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2852201

7 April 2017

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2852201

27 September 2017

Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2852201

27 September 2017

A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2852201

27 September 2017

A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2852201

27 September 2017

Hormone-refractory prostate cancer: a multi-step and multi-event process

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2852201

27 September 2017

Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2852201

27 September 2017

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2852201

27 September 2017

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2852201

27 September 2017

Meta-analysis: formulating, evaluating, combining, and reporting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2852201

27 September 2017

Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2852201

27 September 2017

Cancer statistics, 2003.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2852201

30 May 2018

Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group Trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2852201

30 May 2018

Treatment of genitourinary tumours with cis-dichlorodiammineplatinum(II): experience in 250 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2852201

30 May 2018

A critical analysis of response criteria in patients with prostatic cancer treated with CIS-diamminedichloride platinum II

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2852201

30 May 2018

Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP308

21 January 2018

Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP308

21 January 2018

A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP308

21 January 2018

Small-sample performance of the robust score test and its modifications in generalized estimating equations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP308

21 January 2018

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP308

21 January 2018

A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP308

21 January 2018

Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP308

21 January 2018

Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2852201

28 November 2018

Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19633053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDP308

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633053%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633053%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633053%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24599547&oldid=1966868176"